Chronic granulomatous reaction in patients receiving vaccine immunotherapy for metastatic melanoma

Various agents such as melanoma-associated antigen 3 (MAGE-3), interleukin-2 (IL-2), gp100, and toll-like receptor agonists have been investigated as therapies for melanoma because of their ability to stimulate an immune response against melanocytes. We report on 3 patients with metastatic melanoma who, after receiving immunotherapy injections, had persistent subcutaneous nodules at their injection sites. One patient's nodules were shown to be a granulomatous reaction on histopathology.